ICMR signs agreements for first-in-human clinical trials of four new molecules

The Indian Council of Medical Research (ICMR) has formalised Memoranda of Agreements (MoAs) with multiple sponsors under its Network of Phase 1 Clinical Trials. The agreements mark the commencement of First-in-Human Clinical Trials for four molecules. These trials include research into a small molecule for multiple myeloma in collaboration with Aurigene Oncology Limited, Zika vaccine development with Indian Immunologicals, a seasonal influenza vaccine trial with Mynvax Private, and CAR-T cell therapy for chronic lymphocytic leukaemia in partnership with ImmunoACT.

Union Health and Family Welfare Minister, J P Nadda, acknowledged the strategic collaboration between ICMR and leading industry and academic partners as a significant milestone in the pursuit of affordable treatments. He stated, “This initiative positions India to emerge as a global leader in healthcare innovation.”

Dr Rajiv Bahl, Secretary of the Department of Health Research and Director General of ICMR, emphasised the potential of the collaboration. He said, “This collaboration reflects our commitment to advancing clinical research in India through strategic public-private partnerships. Establishing Phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to expand this network further, ensuring that India continues to lead in the development of innovative and affordable healthcare solutions.”

Dr Bahl also mentioned the broader impact of ICMR’s initiatives, such as the Network for Phase 1 Clinical Trials, INTENT Network, and MedTech Mitra, which align with the government’s vision of a “Viksit Bharat” (Developed India). He referenced ICMR’s role in the development of Covaxin in collaboration with Bharat Biotech as evidence of the organisation’s dedication to affordable healthcare.

The ICMR Network for Phase 1 Clinical Trials is composed of four institutions across India—KEMH & GSMC in Mumbai, ACTREC in Navi Mumbai, SRM MCH&RC in Kattankulathur, and PGIMER in Chandigarh. These sites are supported by a Central Coordinating Unit at ICMR Headquarters in New Delhi. The network aims to build India’s capacity to conduct early-phase clinical trials, backed by infrastructure and manpower at each site.

The signing of these agreements strengthens the partnerships ICMR has established with key industry stakeholders. It demonstrates the institute’s commitment to building a clinical trial ecosystem in India, reducing dependency on international resources, and supporting the development of affordable healthcare solutions.